Cervical Conization (Cone Biopsy) in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS:

• Women with colposcopic biopsy-confirmed CIN II or CIN III (HSIL) in whom conservative surveillance is inappropriate (age ≥25, immunocompromise, poor compliance with follow-up, or persistent lesion >24 months)

• Women with adenocarcinoma in situ (AIS) of the cervix regardless of fertility intent (excision mandatory; hysterectomy preferred if childbearing complete)

• Women with a positive high-risk HPV co-test and unsatisfactory colposcopy (squamocolumnar junction not fully visualised) requiring diagnostic excision

• Women with discordant cytology–colposcopy (e.g., HSIL cytology with negative or CIN I biopsy) per ASCCP 2019 guidelines

• Early microinvasive cervical carcinoma FIGO Stage IA1 (≤3 mm depth, ≤7 mm width) in patients wishing to preserve fertility

• REQUIRED PRE-OPERATIVE DIAGNOSTICS:

• Cervical cytology (liquid-based Pap smear) within 6 months

• High-risk HPV DNA genotyping (Cobas, Aptima, or equivalent platform)

• Colposcopy with directed punch biopsies and endocervical curettage (ECC)

• p16/Ki-67 dual immunostaining on biopsy if CIN grade is equivocal

• Full blood count, coagulation screen (PT/aPTT/INR), blood group and screen

• Pregnancy test (serum β-hCG) — conization in pregnancy requires specialist multidisciplinary team input

• Pelvic MRI (if microinvasion or glandular disease suspected on biopsy to exclude stromal invasion >3 mm before planning conservative surgery)

• STI screen (gonorrhoea, chlamydia, bacterial vaginosis) and treatment prior to procedure to minimise infection risk

• CONTRAINDICATIONS:

• Active lower genital tract infection (must be treated and resolved prior to scheduling)

• Known bleeding diathesis or therapeutic anticoagulation not bridgeable peri-operatively

• Pregnancy (relative contraindication; LEEP/CKC may be performed in second trimester for confirmed high-grade lesions with significant risk of occult invasion — requires tertiary-centre expertise)

• FIGO Stage IA2 or higher invasive carcinoma (requires radical trachelectomy or hysterectomy; conization alone is oncologically inadequate)

• Women with prior cervical stenosis or surgically absent cervix

LOOP ELECTROSURGICAL EXCISION PROCEDURE (LEEP / LLETZ): LEEP is the most widely performed first-line excisional technique globally and the preferred method at most Indian and UAE centres for CIN II/III confined to the ectocervix. A thin wire loop energised at 30–50 watts blended current excises the transformation zone in a single or two-pass technique under colposcopic guidance, typically under local anaesthesia (intracervical lignocaine 1–2% with adrenaline 1:100,000) as a day-case procedure. The large-loop excision of the transformation zone (LLETZ) technique removes a specimen averaging 10–15 mm in depth and 20–25 mm in diameter. Thermal artefact at the margins is the principal limitation; experienced operators limit this to <1 mm using optimised waveform settings. Haemostasis is achieved with a ball electrode at 40–60 watts coagulation current or Monsel's solution application. Reported clear-margin rates for CIN III: 85–92% on first excision.

COLD KNIFE CONIZATION (CKC): CKC is performed under general or regional anaesthesia in an operating theatre and remains the gold standard when glandular disease (AIS), microinvasive carcinoma, or a large endocervical lesion is suspected, because it produces thermally unaffected margins that allow unambiguous histopathological assessment. The surgeon uses a scalpel (size 11 or 15 blade) to excise a cone specimen tailored to colposcopic and ECC findings; Sturmdorf sutures or figure-of-eight haemostatic sutures control bleeding. Cone depth typically ranges from 20–25 mm for AIS cases. CKC has the lowest margin-positivity rate among excisional techniques for glandular lesions. It is also the preferred technique in pregnancy when excision is unavoidable. Estimated operative time: 20–40 minutes.

CO₂ LASER CONIZATION: Available at select high-volume gynecologic oncology centres in India (Tata Memorial Hospital, Apollo) and the UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai), CO₂ laser conization offers the advantage of simultaneous haemostasis and a precisely controlled ablation depth (operator-adjustable from 1–30 mm). The laser beam (focused spot size 0.2–0.5 mm, power density 500–2000 W/cm²) vaporises or excises tissue with minimal thermal spread (50–100 µm lateral damage zone), preserving margin clarity. It is particularly useful for women with prior LEEP who have cervical stenosis or a shortened ectocervix. The procedure is typically performed under local anaesthesia or brief sedation.

SEE-AND-TREAT STRATEGY: High-volume referral centres in India and the UAE routinely offer a combined colposcopy and LEEP in a single visit for patients with high-grade cytology and colposcopically visible high-grade lesions (acetowhite epithelium with mosaic/punctation, Reid Colposcopic Index ≥6), avoiding the delay and anxiety of a separate biopsy–wait–treatment pathway. This approach is consistent with ASCCP and BSCCP guidelines for appropriate patient selection and reduces overall healthcare contact burden for international medical tourists.

FERTILITY-SPARING CONSIDERATIONS: All excisional techniques carry a small but measurable risk of cervical insufficiency in subsequent pregnancies (relative risk of preterm birth <34 weeks approximately 1.7× for LEEP; 2.5–3.0× for CKC). For women planning future pregnancy, LEEP with the smallest clinically adequate cone dimensions is preferred. Cervical length monitoring by transvaginal ultrasound from 16 weeks gestation is recommended post-conization. Prophylactic cervical cerclage is not routinely indicated but may be considered when post-conization cervical length is <25 mm at 16–24 weeks.

PRE-ARRIVAL (2–4 WEEKS BEFORE TRAVEL):

• GAF Healthcare's medical coordination team reviews all prior cytology reports, colposcopy findings, biopsy histology, and HPV genotyping results via secure teleconsultation with the treating gynecologic oncologist.

• Pre-operative blood tests (CBC, coagulation, blood group, β-hCG, STI screen) can be completed at the patient's home country with results forwarded digitally; tests not available locally are repeated on Day 1 of arrival.

• Anaesthesia pre-assessment completed remotely for patients requiring general anaesthesia (ASA classification, airway assessment questionnaire, ECG if indicated by age/comorbidity).

• Any concurrent lower genital tract infection is treated and confirmed resolved before travel is booked.

• GAF Healthcare issues a detailed itinerary covering flight dates, airport transfer, hotel/hospital guest-house accommodation, and the procedure date.

DAY 1 — ARRIVAL & HOSPITAL REGISTRATION:

• Airport pickup in air-conditioned, dedicated vehicle; GAF patient coordinator accompanies the patient and attendant throughout.

• Hospital registration, ID verification, and insurance/self-pay financial counselling completed.

• Meeting with the treating consultant gynecologic oncologist and, if applicable, the gynecologic oncology multidisciplinary team for final confirmation of procedure type (LEEP vs CKC vs laser).

• Repeat colposcopy if >3 months have elapsed since the last examination or if clinical findings require re-mapping.

• Pre-operative anaesthetic review and consent obtained.

DAY 2 (OR DAY 1 AFTERNOON) — THE PROCEDURE:

• LEEP/Laser: Performed as day-case under local anaesthesia; total procedure time 15–30 minutes. Patient observed for 2–3 hours post-procedure for bleeding, vasovagal response, and pain before discharge.

• CKC: Performed under general or spinal anaesthesia; patient admitted to ward post-operatively and typically discharged same evening or following morning after ensuring haemostasis and adequate oral analgesia.

• Haemostatic pack may be placed intravaginally and removed after 24 hours (CKC patients).

• Specimen immediately transferred to histopathology in formalin; preliminary margin assessment available in 48–72 hours; final report within 5–7 working days.

DAYS 2–7 — EARLY RECOVERY (IN-COUNTRY):

• Mild-to-moderate cramping managed with NSAIDs (ibuprofen 400 mg TDS or naproxen 500 mg BD); opioid analgesia rarely required.

• Light brownish vaginal discharge is expected for 2–4 weeks; patients are instructed on warning signs (frank red bleeding soaking >1 pad/hour, fever >38°C, offensive discharge, severe pelvic pain) requiring immediate medical review.

• No tampons, sexual intercourse, or swimming for a minimum of 4 weeks post-procedure.

• Heavy lifting (>5 kg) avoided for 1–2 weeks.

• GAF coordinator arranges a Day 5–7 post-operative review with the operating surgeon to assess healing, discuss preliminary histopathology, and confirm fit-to-fly status.

FIT-TO-FLY ASSESSMENT (DAY 7–14):

• Clearance criteria: No active bleeding, afebrile for ≥48 hours, pain controlled on oral analgesia, no clinical signs of infection, patient comfortable to mobilise.

• Deep vein thrombosis (DVT) prophylaxis counselling provided: compression stockings recommended for flights >4 hours; low-molecular-weight heparin (LMWH) considered for patients with additional VTE risk factors (BMI >30, prior VTE, combined OCP use).

• Written post-operative summary, histopathology (preliminary or final), and follow-up protocol forwarded to patient's home gynaecologist via GAF's encrypted medical records portal.

LONG-TERM FOLLOW-UP (MONTHS 1–36):

• HPV co-testing (HPV DNA + liquid-based cytology) at 6 months post-procedure — the most sensitive surveillance endpoint.

• If HPV negative and cytology negative at 6 months: annual co-testing for 3 years, then return to routine 5-yearly screening.

• If HPV positive or positive margins on histology: repeat colposcopy at 4–6 months; re-excision (repeat LEEP or CKC) or hysterectomy (if childbearing complete) discussed.

• GAF Healthcare facilitates telemedicine follow-up consultations with the treating specialist for result review and management planning.